# A funded organoid and PDX panel as the go/no-go gate before IND-enabling money

Source: https://onco.cc/ideas/idea-fund-organoid-translation-gate/  
OnCo record `idea-fund-organoid-translation-gate` (Idea). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

Before any academic compound gets money for pre-trial studies, it would have to show activity in a standard panel of patient-derived tumour models run by an independent centre, so weak candidates are stopped early.

## Summary

A central facility maintains a standardised, molecularly characterised panel of patient-derived organoids and xenografts across cancer types (drawing on EurOPDX, the NCI Patient-Derived Models Repository and Human Cancer Models Initiative collections) and tests every candidate nominated for IND-enabling funding in a blinded, pre-registered protocol with clinically relevant exposure. Results are published regardless of outcome. Funding for toxicology and CMC is contingent on passing pre-agreed activity criteria. This replaces the variable, investigator-run efficacy evidence that currently supports translational decisions.

## Fields

- Kind: Idea
- Last checked: 2026-09-08
- Hypothesis: Candidates that pass an independent, blinded PDX/organoid gate have a phase 2 objective response or progression-free survival signal at least twice as often as historical academic candidates that were advanced on investigator-generated data alone.
- Rationale: Retrospective studies show PDX and organoid response tracks patient response for many drug classes; NCI's PDMR and EurOPDX exist but are not used as a formal gate. Independent, blinded testing addresses the reproducibility and selection biases that inflate academic efficacy claims.
- Proposed test: Gate one translational fund's candidates for three years, publishing pass and fail results, and compare downstream clinical signals with the fund's prior ungated cohort.
- Maturity: preclinical-evidence
- Actor: research

## Sources

- NCI Patient-Derived Models Repository: https://pdmr.cancer.gov/

## Connected records

- collections: [Cancer Models (PDCM Finder) & HCMI](https://onco.cc/collections/cancer-models/)
- ideas: [A fast IND-enabling fund that pays for toxicology and manufacturing in eight weeks](https://onco.cc/ideas/idea-fund-ind-enabling-fund/), [Patient-derived organoids to pick ADC payloads](https://onco.cc/ideas/idea-organoid-guided-adc/), [Set aside 3% of grant budgets to replicate findings before translation](https://onco.cc/ideas/idea-fund-replication-set-aside/)
- technologies: [Functional (ex vivo) drug testing](https://onco.cc/technologies/functional-drug-testing/), [Patient-derived organoids](https://onco.cc/technologies/organoids/), [Patient-derived xenografts](https://onco.cc/technologies/pdx-models/)
- bottlenecks: [Lab models that fail to predict what happens in patients](https://onco.cc/bottlenecks/b-preclinical-models/), [The valley of death between lab and product](https://onco.cc/bottlenecks/b-translational-valley/)

---
JSON: https://onco.cc/api/v1/entities/idea-fund-organoid-translation-gate.json